Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have received an average rating of "Moderate Buy" from the eighteen analysts that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $30.18.

A number of equities research analysts have weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Leerink Partners started coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a "market perform" rating and a $16.00 target price on the stock. Stifel Nicolaus cut their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st.

Nurix Therapeutics Trading Down 1.2%

Shares of NASDAQ NRIX traded down $0.15 during mid-day trading on Friday, reaching $12.21. The company had a trading volume of 565,267 shares, compared to its average volume of 836,396. The stock has a market cap of $930.89 million, a price-to-earnings ratio of -4.36 and a beta of 2.15. Nurix Therapeutics has a 52 week low of $8.18 and a 52 week high of $29.56. The business's 50-day moving average is $11.15 and its 200-day moving average is $13.95.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, equities research analysts forecast that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider directly owned 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer directly owned 33,724 shares of the company's stock, valued at approximately $382,092.92. This represents a 15.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,013 shares of company stock valued at $137,096 in the last three months. Insiders own 7.40% of the company's stock.

Institutional Trading of Nurix Therapeutics

Several large investors have recently bought and sold shares of the stock. FMR LLC lifted its stake in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after buying an additional 10,047,329 shares during the period. Vanguard Group Inc. raised its stake in Nurix Therapeutics by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company's stock worth $52,452,000 after acquiring an additional 69,856 shares during the last quarter. Wellington Management Group LLP lifted its position in Nurix Therapeutics by 3.0% during the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after acquiring an additional 104,500 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in Nurix Therapeutics by 2.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,428,283 shares of the company's stock valued at $28,849,000 after purchasing an additional 47,855 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its stake in Nurix Therapeutics by 97.3% during the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after purchasing an additional 1,036,999 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.